Patents by Inventor Martha J. Kelly
Martha J. Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11986481Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: GrantFiled: December 22, 2023Date of Patent: May 21, 2024Assignees: Madrigal Pharmaceuticals, Inc., Hoffmann-La Roche Inc.Inventors: Martha J. Kelly, Rebecca Taub, Edward Hung Yang Chiang
-
Publication number: 20240148742Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: ApplicationFiled: December 22, 2023Publication date: May 9, 2024Inventors: D. Keith HESTER, II, Robert J. DUGUID, Martha J. KELLY, Anna CHASNOFF, Gang DONG, Edwin L. CROW, Lianhe SHU, Ping WANG, Duk Soon CHOI
-
Publication number: 20240122936Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: ApplicationFiled: December 22, 2023Publication date: April 18, 2024Inventors: D. Keith HESTER, II, Robert J. DUGUID, Martha J. KELLY, Anna CHASNOFF, Gang DONG, Edwin L. CROW, Lianhe SHU, Ping WANG, Duk Soon CHOI
-
Publication number: 20230210856Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: ApplicationFiled: December 15, 2022Publication date: July 6, 2023Inventors: D. Keith HESTER, II, Robert J. DUGUID, Martha J. KELLY, Anna CHASNOFF, Gang DONG, Edwin L. CROW, Lianhe SHU, Ping WANG, Duk Soon CHOI
-
Patent number: 11564926Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: GrantFiled: December 11, 2020Date of Patent: January 31, 2023Assignees: Madrigal Pharmaceuticals, Inc., Hoffmann-La Roche Inc.Inventors: D. Keith Hester, II, Robert J. Duguid, Martha J. Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Lianhe Shu, Ping Wang, Duk Soon Choi
-
Publication number: 20210161904Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: ApplicationFiled: December 11, 2020Publication date: June 3, 2021Inventors: D. Keith HESTER, II, Robert J. DUGUID, Martha J. KELLY, Anna CHASNOFF, Gang DONG, Edwin L. CROW, Lianhe SHU, Ping WANG, Duk Soon CHOI
-
Patent number: 10894050Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: GrantFiled: July 1, 2019Date of Patent: January 19, 2021Assignees: Madrigal Pharmaceuticals, Inc., Hoffmann-La Roche Inc.Inventors: D. Keith Hester, II, Robert J. Duguid, Martha J. Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Lianhe Shu, Ping Wang, Duk Soon Choi
-
Patent number: 9266861Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: GrantFiled: March 17, 2015Date of Patent: February 23, 2016Assignees: Madrigal Pharmaceuticals, Inc., Hoffmann-La Roche Inc.Inventors: D. Keith Hester, II, Robert J. Duguid, Martha J. Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Duk Soon Choi, Lianhe Shu, Ping Wang
-
Publication number: 20150203473Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: ApplicationFiled: March 17, 2015Publication date: July 23, 2015Inventors: D. Keith Hester, II, Robert J. Duguid, Martha J. Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Rebecca Taub, Charles H. Reynolds, Duk Soon Choi, Lianhe Shu, Ping Wang
-
Patent number: 8962623Abstract: A compound of formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, has an Itk inhibitory activity, and is useful as a method for preventing and/or treating atopic dermatitis, and the like.Type: GrantFiled: February 29, 2012Date of Patent: February 24, 2015Assignee: Locus Pharmaceuticals, Inc.Inventors: Rupa S. Shetty, Martha J. Kelly, Bin Liu, Jinming Zou, Kristofer K. Moffett, Younghee Lee, Dora Do-York Wong
-
Publication number: 20140187529Abstract: A compound of formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, has an Itk inhibitory activity, and is useful as a method for preventing and/or treating atopic dermatitis, and the like.Type: ApplicationFiled: February 29, 2012Publication date: July 3, 2014Applicant: LOCUS PHARMACEUTICALS, INC.Inventors: Rupa S. Shetty, Martha J. Kelly, Bin Liu, Jinming Zou, Kristopher K. Moffett, Younghee Lee
-
Patent number: 5675037Abstract: This application relates to a process for selectively monoacylating hydrazines by reacting unsubstituted or monoalkylhydrazines with trichloromethyl aryl ketones.Type: GrantFiled: December 17, 1990Date of Patent: October 7, 1997Assignee: Rohm and Haas CompanyInventor: Martha J. Kelly
-
Patent number: 5110986Abstract: This application relates to a process for preparing a N-t-alkyl-1,2-diacylhydrazine by reacting a 1,3,4-oxadiazole with a tertiary alkyl cation precursor in the presence of a strong acid catalyst. Preferably, the 1,3,4-oxadiazole is a 2,5-disubstituted-1,3,4-oxadiazole and more preferably a 2,5-diaryl-1,3,4-oxadiazole. The strong acid catalyst is preferably a sulfur containing acid and more preferably sulfuric acid.Type: GrantFiled: April 26, 1988Date of Patent: May 5, 1992Assignee: Rohm and Haas CompanyInventor: Martha J. Kelly
-
Patent number: 4954655Abstract: This application relates to a process for preparing alkylhydrazines from an alkene and hydrazine with an acid catalyst. More particularly, it relates to a process for preparing t-butylhydrazine from hydrazine and isobutylene in aqueous acid.Type: GrantFiled: March 31, 1989Date of Patent: September 4, 1990Assignee: Rohm and Haas CompanyInventor: Martha J. Kelly